

Claim 1 (amended):

A1 1. A peptide composition consisting essentially of an arginyl-glutamine dipeptide formulated as a nutrient formulation, wherein the arginine residue is the amino terminus of said dipeptide and the glutamine residue is the carboxy terminus of said dipeptide and wherein the dipeptide is present in said composition at a concentration of about 0.1% to about 25% by weight of said formulation.

Claim 13 (amended):

A2 13. A method for promoting an increased mucosal IgA immune response in a human or animal, said method comprising administering to a human or animal an effective amount of a dipeptide composition consisting essentially of an arginyl-glutamine dipeptide formulated as a nutrient formulation, wherein the arginine residue is the amino terminus of said dipeptide and the glutamine residue is the carboxy terminus of said dipeptide.